You can find out more about NPF's National Medical Director, Dr. Michael S. Okun, by also visiting the NPF Center of Excellence, University of Florida Center for Movement Disorders & Neurorestoration.
Recently much attention has been focused on the use of stem cells as a potential treatment for Parkinson’s disease (PD). Now, researchers at Memorial Sloan-Kettering Cancer Center in New York City report that they have successfully placed embryonic stem cells into several PD animal models. The findings are published in the November 6 issue of Nature. This month, I will review this exciting paper and outline the “next steps” for stem cell therapy.
In the study, Sonya Kriks, Ph.D., and the research team used embryonic stem cells to generate dopamine neuron cells. Then, they transplanted the new cells into 6-hydroxy-dopamine-lesioned mice and rats (laboratory models with induced Parkinsonism). The new cells reportedly survived, and in two important tests of behavior, the animals’ Parkinsonian symptoms improved. After researchers implanted the new cells into monkeys (which are considered evolutionarily closer to humans) they also found that the cells survived, and test results showed positive behavioral benefits as well. Finally, no tumors were found in the laboratory models, which is important because tumor formation has been an ongoing concern for stem cell biologists interested in translating discoveries from the “bench-to-bedside.”
As patients and families continue to ask the key question, “Why don’t we start transplanting stem cells for this generation of Parkinson’s disease sufferers?” we must keep in mind findings from previous research. In the past, simple cell transplantation experiments proved that, like Dr. Kriks and her team, “we can” place cells in the brain (this was done in human brain), and that with special techniques we can ensure cell survival. Unfortunately, we also have discovered that these transplanted cells can only reconstitute a small percentage of the critically affected brain regions in PD.
Too, we know that with simple cell transplantation, the symptoms addressed are usually motor---tremor, stiffness and slowness. Behavioral issues such as walking, talking and thinking have not been adequately addressed. The reason for this is thought to be related to the complexity of the brain and “neural” circuitry. Also, recent cell transplants in humans have resulted in a difficult-to-treat side effect called “runaway dyskinesia.” And, we know from brains that have been “turned in” (post-mortem brain bank specimens), that transplanted cells have become “sick” with PD proteins that promote disease progression.
That said, this research by Dr. Kriks’ team and other scientists is proving critical in helping to move stem cell research forward and to bring new therapies to people with PD. However, many challenges still need to be overcome before these therapies are ready for prime-time. The new generation of stem cell scientists will have to better address the following: 1. all symptoms of PD (motor and non-motor/behavioral); 2. levodopa resistant symptoms (such as walking, talking and thinking); and 3. how to protect newly transplanted cells against “sickness.” Additionally, any new therapy will need to be proven safe, ensuring runaway behavioral manifestations and other adverse events do not occur. Future models also will need to prevent tumor formation.
We remain encouraged that stem cell therapy can play a role in the treatment of PD in the future, and we look forward to a new generation of scientists who will pursue these current challenges. We congratulate Dr. Kriks and the other study authors for having taken another important step forward. We would encourage stem cell researchers to continue to “think outside the box” and to combine their cell based techniques with novel delivery systems, which we hope will lead to developments of new therapies that will improve and rescue much larger areas of brain in people with PD.
Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011 Nov 6. doi:
10.1038/nature10648. [Epub ahead of print] PubMed PMID: 22056989.
Posted: 12/5/2011 7:05:18 AM by
Browse current and archived What's Hot in PD? articles, the National Parkinson Foundation's monthly blog for people with Parkinson's written by our National Medical Director, Dr. Michael S. Okun.
The End for Levodopa Phobia: New Study Shows Sinemet is a Safe Initial Therapy for Treatment of Parkinson's Disease
Is light therapy a potential treatment modality in Parkinson’s disease?
How does the most common genetic cause of Parkinson’s Disease (LRRK2) cause Parkinson’s disease and could it be used to help develop a better therapy?
An Update on DAT Scanning for Parkinson’s Disease Diagnosis
Could Northera (Droxidopa) Be an Alternative Treatment for Low Blood Pressure and Passing Out Symptoms?
The Dream of a Pill Free Existence and the Continuous Dopaminergic Pump for the Treatment of Parkinson's Disease
Should I take Inosine to Raise my Uric Acid Levels and Treat my Parkinson’s Disease?
Could Fungus and Mold be an Important Contributor to Parkinson’s Disease?
Pimavanserin and the Hope for a Better Drug for Hallucinations and Psychosis in Parkinson’s Disease
Halting of the Creatine Study
The Importance of Identifying and Treating Caregiver Strain
Putting Parkinson’s Disease Information into the Palm of Your Hand: Parkinson’s Enters the Smartphon
What Parkinson’s Disease Patients Need to Know about H. Pylori Gastrointestinal Infections
A2A Receptor Antagonists and Parkinson’s Disease Treatment
Another Setback for Trophic Factor Treatment in Parkinson's Disease
IPX066 and What Patients Really Want in New Carbidopa/Levodopa (Sinemet) Formulations
The Weather Forecast for Parkinson’s Disease Calls for Worldwide Economic Storm
Defeating the Barriers to Implementing Exercise Regimens in Parkinson’s Disease Patients
When should you start medication therapy for Parkinson’s disease?
Neurologist Care Reduces Hospitalizations in Parkinson's Disease
A Victory in Court for Parkinson's Disease Patients who Require Ongoing Rehabilitative Therapies
Given the recent FDA announcement about Mirapex (pramipexole), should I be worried about dopamine agonists?
What about the new Parkinson’s Disease Vaccine? What should I know?
Caffeine as a Potential Treatment for Parkinson’s Disease
Time to Consider GPi DBS for Parkinson’s Disease: A Shift in the Practice of Patient Selection for DBS
A New Treatment for Parkinson’s Disease-Related Constipation
Too Many Pills: Improving Delivery Systems for Parkinson’s Disease Drugs
Measuring Quality and Assessing Depression in Parkinson's Disease
Watch out for Unexpected Obstacles if You Use a Cueing Strategy to Break Freezing of Gait in Parkinson’s Disease
Pill Color, Generic Medications and Insurance Issues: Important Medication-Related Tips for the Parkinson’s Disease Patient
Are Blood Tests for Parkinson’s Disease on the Horizon?
Placing Stem Cells in Animal Models of Parkinson’s Disease: Another Important Step
Important News for the Parkinson’s Disease Community: More Evidence that Sinemet and Madopar are Not Toxic and do Not Accelerate Disease Progression
The Case for All Parkinson’s Disease Patients to be Co-managed by a Primary Care-Neurologist Team
Scientists say Research on Brain Proteins Involved in Parkinson’s Disease is “Shaping” Up
Who Actually Takes Care of Most of the Parkinson’s Patients Worldwide: The Need for Education and the Parkinson’s Toolkit
If you are Dizzy or Passing Out, it could be Your Parkinson’s Disease or Parkinson’s Disease Medications
How Will Group Visits for Parkinson’s Disease Fit into the Future of Parkinson’s Disease Care?
Why Patients Should be Wary of Chelation Therapy for Parkinson’s Disease
Opening the Door to Gene Therapy in Parkinson’s Disease: The Need for Refinement of the Technology and Approach
Does it Matter if I Can’t Get Brand Sinemet?
Should I get a DaTscan or PET scan to confirm my diagnosis of Parkinson’s disease?
A Critical Reappraisal of the Worst Drugs in Parkinson’s Disease
Environmental Risks for PD: Manganese, Welding, Mining, and Parkinsonism
Calling for the FDA to Revise the Eight Sinemet a Day Rule
Dry Cleaning Solvents and Potential Environmental Risks for Developing Parkinson’s Disease
Maintaining the Balance: Why Parkinson’s Disease Patients Need to Understand Drug Recalls, Withdrawals, and Safety Alerts
Shining a Light on Parkinson’s Disease: Optogenetics Has a Bright Future in Research
Poor Medication Management of Parkinson's Disease During Hospital Admissions: Patients and Families Can Improve Their Hospital-Based Management
Why Are Patches and Continuous Release Technology a Big Deal to Parkinson's?
Is the PD SURG Trial Another Surge Forward for DBS Therapy?
Cycling in PD in Those Who Can’t Walk: Is it Possible?
New iPS Stem Cells for PD: What Does it Mean?
Time for Comprehensive Care Networks for PD
Is Parkinson's Disease a Prion Disease?
Parkinson's Disease Linked to Gaucher's Disease
Brain Cells Keep Time Stamps: Implications for Parkinson's Disease Therapies
Is it Safe to Have an MRI with a DBS in Place?
Take Care of Your Bones as They Are Affected in Parkinson's Disease (Even in Men)
Is it Time to Start Paying Attention to Pain Symptoms in Parkinson's Disease Patients?
Glutathione Fails to Demonstrate Significant Improvement in PD Symptoms
Keeping an Eye on Trials Important to the Parkinson's Disease Patient
Increased Risk of Melanoma in Parkinson's Disease
Finally a DBS Expert Consensus Statement Aimed at Their True Customers: The Patients
Pesticides and Environmental Exposure in Parkinson's disease: Should We Stay Away From the Stink Truck?
Is Exercise Effective Treatment and Protection Against PD?
Why are Transplant Trials Struggling to Succeed in the Treatment of PD?
Are Monoamine Oxidase Inhibitors Disease Modifying or Neuroprotective in PD?
Update on Gene Therapy for Parkinson's Disease